Cipla, a leading drug manufacturer, has announced that it has got final sanction from the US Food and Drug Administration (USFDA) to market Pamidronate disodium injection.

The approval has been granted for 30 mg/vial, 60 mg/vial and 90 mg/ vial .

According to the sources, Pamidronate disodium is indicated for the treatment of Paget`s disease of bone and high blood calcium levels. The drug also used in the treatment of osteoporosis, to reduce bone pain associated with certain illnesses and to treat bone loss due to breast cancer.

Scrip of Cipla declined Rs 2.1, or 1.13 percent, to settle at Rs 183 on Bombay Stock Exchange (BSE).The total volume of shares traded was 231,412 at the BSE.